This is the podcast for the ASH 2021 Focus on CAR T-Cell Therapy, presented by Dr Rachel Giles (Medicom).
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« BMI, alcohol intake, cholesterol and WBC proportions tied to ALS Next Article
Welcome to our Focus Edition on CAR T-cell therapy news »
« BMI, alcohol intake, cholesterol and WBC proportions tied to ALS Next Article
Welcome to our Focus Edition on CAR T-cell therapy news »
Table of Contents: ASH 2021 Focus on CAR T-Cell Therapy
Featured articles
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
CAR T-cell Therapy
Most re-hospitalisations within first month from CAR T-cell infusion
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL
Improved QoL with axi-cel versus standard-of-care in R/R LBCL
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy